Pharma Stocks under Review -- Impax Laboratories, Sanofi, GW Pharma, AcelRx Pharma, and Salix Pharma

LONDON, July 23, 2014 /PRNewswire/ --

On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, and the index has advanced 1.58% in the last one month. Investor-Edge has initiated coverage on the following equities: Impax Laboratories Inc. (NASDAQ: IPXL), Sanofi (NYSE: SNY), GW Pharmaceuticals PLC (NASDAQ: GWPH), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Salix Pharmaceuticals Ltd (NASDAQ: SLXP). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

On Tuesday, Impax Laboratories Inc.'s stock recorded a trading volume of 0.58 million shares, lower than its three months average volume of 0.69 million shares. The stock finished the day at $29.01, up 0.24%, and registered an intraday range of $28.79 and $29.25. Impax Laboratories Inc.'s shares have advanced 4.65% in the previous three trading sessions and 11.36% in the last three months. Also, the stock has gained 15.39% on YTD basis. Furthermore, the company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $28.38 is above its 200-day moving average of $25.09. Additionally, shares of the company traded at a PE ratio of 49.86 and have a Relative Strength Index (RSI) of 50.07. Sign up and read the free notes on IPXL at:

http://www.Investor-Edge.com/IPXL-23Jul2014

Sanofi's stock gained 0.68%, to close Tuesday's session at $51.82, after oscillating between $51.61 and $52.05. The stock recorded a trading volume of 0.58 million shares, below its three months average volume of 0.95 million shares. Over the last one month, Sanofi's shares have declined 4.95%. Also, over the past three months and from the beginning of 2014, the company's stock has fallen by 2.94% and 3.37%, respectively. The stock is trading above its 200-day moving average. The company stock's 50-day moving average of $52.99 is above its 200-day moving average of $51.80. Further, Sanofi's stock has an RSI of 40.23. The complimentary notes on SNY can be downloaded as in PDF format at:

http://www.Investor-Edge.com/SNY-23Jul2014

On Tuesday, GW Pharmaceuticals PLC's stock finished the session 1.88% higher at $88.24. A total of 1.00 million shares were traded, which was below its three months average volume of 1.34 million shares. The stock moved between $87.58 and $92.00 during the session. Over the last one month, shares in GW Pharmaceuticals PLC have lost 5.29%. However, the stock has rallied 44.99% over the past three months and 112.42% since the start of this year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $80.84 is greater than its 200-day moving average of $56.39. Shares of the company have an RSI of 49.39. Register for free on Investor-Edge and access the latest research on GWPH at:

http://www.Investor-Edge.com/GWPH-23Jul2014

Shares in AcelRx Pharmaceuticals Inc. fluctuated between $9.92 and $10.28 before ending Tuesday's session down 1.19%, at $9.96. The company's stock reported a trading volume of 0.64 million shares, which was at par with its three months average volume. Further, shares of AcelRx Pharmaceuticals Inc. have surged 10.79% over the past three trading sessions. However, the stock has declined 3.95% over the last one month and 11.94% on YTD basis. The stock is trading above its 50-day moving average. The stock's 200-day moving average of $10.17 is greater than its 50-day moving average of $9.77. Moreover, shares of the company have an RSI of 49.22. The complete research on ACRX is available for free at:

http://www.Investor-Edge.com/ACRX-23Jul2014

Salix Pharmaceuticals Ltd's stock advanced 0.86%, to close Tuesday's session at $131.26, after vacillating between $130.26 and $134.26. The stock recorded a trading volume of 0.72 million shares, below its three months average volume of 1.11 million shares. Over the last one month and previous three months, Salix Pharmaceuticals Ltd's shares have surged 5.84% and 20.34%, respectively. Also, from the beginning of 2014, the stock has gone up 45.94%. The company's stock is trading above its 50-day and 200-day moving averages. Salix Pharmaceuticals Ltd's 50-day moving average of $119.78 is above its 200-day moving average of $100.29. Further, the stock traded at a PE ratio of 67.89 and has an RSI of 54.26. Free in depth research on SLXP is available at:

http://www.Investor-Edge.com/SLXP-23Jul2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED